ONTX - Onconova Therapeutics Inc Stock Price, Fair Value and News

0.66USD+0.02 (+3.13%)Delayed

Market Summary

USD0.66+0.02

Delayed

3.13%

ONTX Stock Price

View Fullscreen

ONTX RSI Chart

ONTX Valuation

Market Cap

16.7M

Price/Earnings (Trailing)

-0.92

Price/Sales (Trailing)

73.89

EV/EBITDA

-0.02

Price/Free Cashflow

-0.94

ONTX Price/Sales (Trailing)

ONTX Profitability

EBT Margin

-8384.07%

Return on Equity

-301.85%

Return on Assets

-99.91%

Free Cashflow Yield

-106.76%

ONTX Fundamentals

ONTX Revenue

Revenue (TTM)

226.0K

ONTX Earnings

Earnings (TTM)

-18.2M

Earnings Growth (Yr)

13.71%

Earnings Growth (Qtr)

-19.1%

Breaking Down ONTX Revenue

Last 7 days

1.5%

Last 30 days

-2.9%

Last 90 days

-1.5%

Trailing 12 Months

-45%

How does ONTX drawdown profile look like?

ONTX Financial Health

Current Ratio

1.93

ONTX Investor Care

Shares Dilution (1Y)

20.66%

Diluted EPS (TTM)

-0.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	226.0K	0	0	0
2023	226.0K	226.0K	226.0K	226.0K
2022	226.0K	226.0K	226.0K	226.0K
2021	235.0K	236.0K	227.0K	226.0K
2020	2.2M	201.0K	204.0K	231.0K
2019	1.5M	1.7M	1.9M	2.2M
2018	1.1M	1.3M	1.3M	1.2M
2017	4.3M	2.4M	817.0K	787.0K
2016	12.8M	14.9M	15.0M	5.5M
2015	467.0K	465.0K	2.0M	11.5M
2014	4.1M	3.6M	2.6M	800.0K
2013	46.8M	47.5M	5.8M	4.8M
2012	12.7M	23.8M	35.0M	46.2M
2011	0	0	0	1.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Onconova Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 14, 2024	fruchtman steven m	sold (taxes)	-7,854	0.9	-8,727	president, chief executive off
Mar 14, 2024	guerin mark patrick	sold (taxes)	-2,331	0.9	-2,591	cfo and coo
Mar 13, 2024	fruchtman steven m	acquired	-	-	23,111	president, chief executive off
Mar 13, 2024	guerin mark patrick	acquired	-	-	8,666	cfo and coo
Feb 07, 2024	guerin mark patrick	sold (taxes)	-1,636	0.67	-2,443	cfo and coo
Feb 07, 2024	fruchtman steven m	acquired	-	-	21,320	president, chief executive off
Feb 07, 2024	guerin mark patrick	acquired	-	-	6,900	cfo and coo
Feb 07, 2024	fruchtman steven m	sold (taxes)	-6,172	0.67	-9,212	president, chief executive off
Aug 03, 2023	fruchtman steven m	sold (taxes)	-4,791	1.01	-4,744	president, chief executive off
Aug 03, 2023	guerin mark patrick	sold (taxes)	-1,450	1.02	-1,422	cfo and coo

Which funds bought or sold ONTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	13,958	53,318	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	37,187	37,187	-%
May 15, 2024	Royal Bank of Canada	reduced	-67.84	-	-	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-3.57	8,994	38,367	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-11,549	-	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	reduced	-6.28	15,666	73,797	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-1.75	874	3,522	-%
May 15, 2024	Vermillion & White Wealth Management Group, LLC	unchanged	-	1,357	5,184	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-506	-	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	4,986	19,044	-%

Are Funds Buying or Selling ONTX?

Are funds buying ONTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ONTX

No. of Funds

Unveiling Onconova Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 08, 2024	viriom, inc.	6.5%	1,645,100	SC 13D
Feb 14, 2022	cvi investments, inc.	0%	0	SC 13G/A
Oct 01, 2021	cvi investments, inc.	5.7%	1,175,000	SC 13G
Jan 08, 2021	lincoln park capital fund, llc	6.52%	13,639,411	SC 13G
Jan 08, 2021	sabby management, llc	0.11%	206,730	SC 13G/A
Feb 19, 2020	683 capital management, llc	1%	1e+05	SC 13D/A
Feb 14, 2020	tyndall capital partners l p	0.1%	26,042	SC 13G/A
Feb 14, 2020	point72 asset management, l.p.	2.6%	3e+06	SC 13G/A
Feb 14, 2020	ecor1 capital, llc	0%	0	SC 13G/A
Jan 13, 2020	sabby management, llc	0.15%	206,730	SC 13G/A

Recent SEC filings of Onconova Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
Apr 29, 2024	10-K/A	Annual Report
Apr 16, 2024	8-K	Current Report
Apr 16, 2024	D	D
Apr 16, 2024	DEFA14A	DEFA14A
Apr 12, 2024	3/A	Insider Trading
Apr 11, 2024	3/A	Insider Trading
Apr 08, 2024	SC 13D	13D - Major Acquisition
Apr 04, 2024	8-K	Current Report

Peers (Alternatives to Onconova Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Onconova Therapeutics Inc News

Latest updates

Onconova Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	0%	56,000	56,000	57,000	57,000	56,000	56,000	57,000	57,000	56,000	56,000	57,000	57,000	56,000	57,000	66,000	56,000	52,000	30,000	63,000	2,022,000	1,040,500
Operating Expenses	16.6%	5,268,000	4,518,000	5,146,000	4,667,000	6,193,000	5,790,000	5,698,000	4,177,000	4,188,000	3,819,000	4,047,000	4,702,000	4,154,000	6,312,000	6,340,000	7,395,000	5,177,000	5,757,500	5,161,000	5,655,000	7,309,000
S&GA Expenses	-100.0%	-	2,084,000	2,686,000	2,211,000	2,113,000	2,017,000	2,105,000	2,139,000	2,186,000	2,074,000	2,284,000	2,850,000	2,217,000	1,778,000	2,147,000	2,594,000	1,807,000	1,711,000	1,640,000	1,760,000	3,234,000
R&D Expenses	-21.4%	1,912,000	2,434,000	2,460,000	2,456,000	4,080,000	3,773,000	3,593,000	2,038,000	2,002,000	1,745,000	1,763,000	1,852,000	1,937,000	4,534,000	4,193,000	4,801,000	3,370,000	4,046,500	3,521,000	3,895,000	4,075,000
EBITDA Margin	0.0%	-83.76	-83.76	-83.83	-83.84	-83.84	-83.84	-71.45	-71.45	-71.45	-71.45	-110	-106	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	68,000
EBT Margin	0%	-83.84	-83.84	-83.91	-83.91	-83.91	-83.91	-71.52	-71.52	-71.52	-71.52	-110	-106	-	-	-	-	-	-	-	-	-
Net Income	-19.1%	-4,983,000	-4,184,000	-4,739,000	-4,250,000	-5,775,000	-5,420,000	-5,398,000	-4,024,000	-4,122,000	-3,764,000	-3,453,000	-4,231,000	-4,715,000	-6,429,000	-6,241,000	-7,395,000	-5,092,000	-5,747,000	-4,595,000	-3,561,000	-7,600,000
Net Income Margin	4.2%	-80.34	-83.84	-89.31	-92.23	-91.23	-83.91	-76.58	-67.98	-68.89	-71.52	-82.94	-91.59	-	-	-	-	-	-	-	-	-
Free Cashflow	0.1%	-4,424,000	-4,430,000	-4,469,000	-4,490,000	-4,543,000	-3,884,000	-3,900,000	-4,214,000	-4,296,000	-4,265,000	-4,267,000	-4,307,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-19.9%	18.00	23.00	27.00	30.00	35.00	39.00	44.00	48.00	51.00	55.00	60.00	44.00	49.00	20.00	25.00	28.00	32.00	24.00	6.00	9.00	11.00
Current Assets	-19.9%	18.00	23.00	27.00	30.00	35.00	39.00	44.00	48.00	51.00	55.00	60.00	44.00	49.00	20.00	25.00	28.00	32.00	23.00	6.00	8.00	11.00
Cash Equivalents	-21.3%	16.00	21.00	25.00	30.00	34.00	39.00	43.00	47.00	51.00	55.00	59.00	44.00	48.00	19.00	24.00	27.00	31.00	23.00	5.00	6.00	10.00
Net PPE	-18.2%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	1.2%	12.00	12.00	13.00	12.00	12.00	11.00	10.00	10.00	9.00	9.00	10.00	11.00	12.00	14.00	13.00	13.00	11.00	12.00	12.00	13.00	13.00
Current Liabilities	2.2%	9.00	9.00	10.00	9.00	9.00	8.00	7.00	6.00	6.00	6.00	7.00	7.00	7.00	10.00	9.00	9.00	7.00	8.00	8.00	9.00	8.00
Shareholder's Equity	-43.6%	6.00	11.00	15.00	19.00	23.00	28.00	33.00	38.00	42.00	46.00	50.00	33.00	37.00	6.00	12.00	16.00	21.00	12.00	-	-	-
Retained Earnings	-1.0%	-487	-482	-478	-473	-469	-463	-458	-452	-448	-444	-440	-437	-433	-428	-422	-415	-408	-403	-397	-393	-389
Additional Paid-In Capital	0.1%	493	493	493	492	492	492	491	491	491	491	490	470	468	435	432	430	428	414	392	388	388
Shares Outstanding	20.5%	25.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00	15.00	16.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	25.00	-	-	-	28.00	-	-	-	109*	-	-	-	98.00	-	-	-	16.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	0.1%	-4,424	-4,430	-4,469	-4,490	-4,543	-3,884	-3,900	-4,214	-4,296	-4,265	-4,267	-4,307	-6,648	-5,468	-5,763	-5,381	-6,463	-5,360	-3,961	-4,909	-6,601
Share Based Compensation	0.3%	333	332	360	273	336	330	305	241	296	261	190	60.00	65.00	94.00	90.00	92.00	93.00	98.00	145	155	650
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	-	-	-
Cashflow From Financing	-	-	-	-	-	-	-	-	-	-	-35.00	19,944	7.00	35,644	279	2,718	1,581	14,779	23,255	2,969	391	33.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ONTX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Condensed Consolidated Statements of Operations (unaudited)
Revenue	$ 56,000	$ 56,000
Operating expenses:
General and administrative	3,356,000	2,113,000
Research and development	1,912,000	4,080,000
Total operating expenses	5,268,000	6,193,000
Loss from operations	(5,212,000)	(6,137,000)
Other income, net	229,000	362,000
Net loss	$ (4,983,000)	$ (5,775,000)
Net loss per share, basic (in dollars per share)	$ (0.24)	$ (0.28)
Net loss per share, diluted (in dollars per share)	$ (0.24)	$ (0.28)
Basic weighted average shares outstanding (in shares)	21,043,458	20,960,171
Diluted weighted average shares outstanding (in shares)	21,043,458	20,960,171

ONTX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 16,390,000	$ 20,821,000
Receivables	18,000	18,000
Prepaid expenses and other current assets	1,745,000	1,821,000
Total current assets	18,153,000	22,660,000
Property and equipment, net	18,000	22,000
Other non-current assets	1,000	1,000
Total assets	18,172,000	22,683,000
Current liabilities:
Accounts payable	6,568,000	5,619,000
Accrued expenses and other current liabilities	2,628,000	3,375,000
Deferred revenue	226,000	226,000
Total current liabilities	9,422,000	9,220,000
Deferred revenue, non-current	2,735,000	2,791,000
Total liabilities	12,157,000	12,011,000
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, none issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.01 par value, 125,000,000 shares authorized, 21,085,935 and 21,003,409 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	211,000	210,000
Additional paid in capital	493,448,000	493,116,000
Accumulated deficit	(487,614,000)	(482,631,000)
Accumulated other comprehensive loss	(30,000)	(23,000)
Total stockholders' equity	6,015,000	10,672,000
Total liabilities and stockholders' equity	$ 18,172,000	$ 22,683,000

About Onconova Therapeutics Inc

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

CEO	Dr. Steven M. Fruchtman M.D.
WEBSITE	onconova.com
INDUSTRY	Biotechnology
EMPLOYEES	16

Onconova Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Onconova Therapeutics Inc? What does ONTX stand for in stocks?

ONTX is the stock ticker symbol of Onconova Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Onconova Therapeutics Inc (ONTX)?

As of Fri May 17 2024, market cap of Onconova Therapeutics Inc is 16.7 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ONTX stock?

You can check ONTX's fair value in chart for subscribers.

What is the fair value of ONTX stock?

You can check ONTX's fair value in chart for subscribers. The fair value of Onconova Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Onconova Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ONTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Onconova Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ONTX is over valued or under valued. Whether Onconova Therapeutics Inc is cheap or expensive depends on the assumptions which impact Onconova Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ONTX.

What is Onconova Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ONTX's PE ratio (Price to Earnings) is -0.92 and Price to Sales (PS) ratio is 73.89. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ONTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Onconova Therapeutics Inc's stock?

In the past 10 years, Onconova Therapeutics Inc has provided -0.62 (multiply by 100 for percentage) rate of return.